CRP and Crohn disease: Patients with a disease duration of <5 years, patients with both ileum and colon involvement, patients with elevated baseline CRP or fCal, patients with history of inadequate response or intolerance to 1 previous biologic, and patients with a prior perianal Crohn's disease-related surgery were more likely to achieve clinical response at Week 16 with ustekinumab IV reinduction than ustekinumab SC maintenance (Figure S5).